You Cannot Audit Your Own Drug Costs. Congress Just Admitted It.
The defining fact of pharmacy benefits is not a price. It is a sightline: under standard contracts, a plan sponsor generally cannot independently verify its own net drug costs — and the proof is that Congress had to legislate audit rights for ERISA plans, effective around 2029. Six things from building an instrument for the years in between.
1. Every net number you have is the counterparty's arithmetic. Approved-auditor lists, aggregate-only rebate reporting, definitions the vendor controls. The FTC — armed with compulsory process — reported difficulty assembling the complete picture. A sponsor with a standard contract is not going to out-see the FTC. That is why our instrument computes an "apparent net" and says the adjective out loud.
2. The rebate argument is over; you are auditing the decoy. Part D rebate pass-through exceeds 99%. The fight most pharmacy committees are still having was won years ago — and the money moved: to fees defined outside the rebate clause, and to affiliated-pharmacy dispensing margin the FTC measured at $7.3 billion above estimated acquisition cost on fifty-one generic drugs, with single-drug markups past 7,700%.
3. The channel is the price. The same generic can cost $33 at acquisition and reimburse near $300 depending on which pharmacy dispenses it. Steering to an affiliated pharmacy is not itself the scandal; steering with pricing unreferenced to NADAC or any acquisition benchmark is how billions happened. In Medicaid, one state auditor found $224.8 million of spread in a single year — and the no-fault settlement record that followed exceeds a billion dollars across twenty-plus states.
4. The generic war is won; stop buying victory parades. At roughly 90% generic dispensing, the substitution lever that defined a generation of pharmacy management is spent. A program selling GDR points today is selling the previous decade's win. The live economics are specialty — half of medicine spending — biosimilar pass-through, and the ladder itself.
5. The IRA moved the tail onto your book. Part D catastrophic liability flipped from 15% plan share to 60%, with a $2,000 member cap concentrating everything above it. The specialty tail that used to be mostly Medicare's is now mostly the plan's — high-claimant discipline now applies to scripts.
6. Always ask whose discount a discount is. 340B is an $81 billion channel whose discount lands upstream of the plan. Negotiated Medicare prices are law, at the government's own self-graded savings estimate. Biosimilar list-price gaps become plan savings only if the low-list product is actually preferred — and the record shows adoption moved on exclusion, not price. A discount booked into the wrong account is a forecast error with a press release.
We built this as an instrument: the net-cost ladder with its honest adjective, the enforcement record in program-design language, the specialty flip, and a term sheet generator that turns each finding into the contract ask that fixes it — starting with adopting the 2029 audit rights by contract today. Browser-only; nothing entered leaves the machine.
Negotiate the audit right before the rate — a discount you cannot verify is a story you are paying to hear.
If your PBM contract renewed tomorrow, could anyone in the building list every dollar the vendor earns from your book that is not called a rebate?